EpicGenetics developed and offers the FM/a Test, an FDA-compliant diagnostic blood test that identifies the immune system biomarkers of fibromyalgia.
According to the company, the new facility is 50,000 square feet and located at 11801 West Olympic in Los Angeles.
The move enables the company to expand its lab, support employee growth and facilitate new research initiatives.
In August, the company announced an FDA approved clinical trial that will be held at Massachusetts General Hospital.
The trial will evaluate the potential for BCG (an inexpensive generic vaccine used globally to prevent tuberculosis) to reverse fibromyalgia.
EpicGenetics is a privately held biomedical company based in Los Angeles, California that developed and manufactures the FM/a Test.
The company is dedicated to improving the diagnosis and treatment of fibromyalgia by offering the first conclusive diagnostic test for fibromyalgia, and by investing in and developing further comprehensive clinical studies at leading medical research centers.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial